VATE INNOVATE Corp.

CIK 0001006837 39 ready 8-Ks latest June 1, 2026, 8:45 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 39

Latest filing June 1, 2026, 8:45 AM ET

Top materiality 0.90

Event mix other_material ×13 · earnings ×9 · regulatory ×5

Sentiment 19 pos · 5 neg · 15 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for VATE

Highest-materiality recent filing

INNOVATE closes $360M 10.5% notes and $54M 9.5% convertible debt refinancing

August 5, 2025, 7:59 PM ET debt materiality 0.90 negative item 1.01 item 2.03 item 3.02 item 9.01

Issued $360.3M New Senior Secured Notes (10.5%, due Feb 2027); exchanged $328.1M of existing 8.5% 2026 notes; $1.9M old notes remain.
Issued $53.5M New Convertible Notes (9.5%, due Mar 2027) exchanging $48.7M of existing convertible notes; conversion price ~$42.31/share.

Read filing →

June 1, 2026, 8:45 AM ET M&A materiality 0.80 neutral item 1.01 item 2.03 item 7.01 item 9.01 ◈ Debt Financings

INNOVATE to sell 75% of Broadcasting to CONX Corp.; $105M bridge loan refinances existing debt

Net to INNOVATE: retains 25% of Broadcasting post-merger; CONX provides up to $75M equity commitment.
May 14, 2026, 4:11 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

INNOVATE Q1 revenue up 33% to $364.8M; net loss narrows to $17.2M; adjusted EBITDA rises 174% to $19.7M

Infrastructure segment revenue $357.9M (+35.1% YoY); DBMG reported backlog $1.6B, adjusted backlog $1.8B.
March 26, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

INNOVATE Q4 rev surges 62% to $382.7M; net loss narrows to $7.8M; backlog $1.8B

Q4 revenue $382.7M (+61.7% YoY); net loss $7.8M ($0.58 EPS) vs $16.9M loss a year ago.
December 16, 2025, 6:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

INNOVATE's MediBeacon receives FDA approval for next-gen TGFR System

MediBeacon (44.7%-owned by VATE) gets FDA nod for TGFR System with reusable sensor.
November 12, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

INNOVATE Q3 rev $347M (+43% YoY); net loss narrows to $9.4M; initiates sales processes for DBM Global and Spectrum

Revenue $347.1M, up 43.3% YoY; net loss attributable to common/preferred $9.4M vs $15.3M; EPS -$0.71 vs -$1.18.
August 5, 2025, 7:59 PM ET debt materiality 0.90 negative item 1.01 item 2.03 item 3.02 item 9.01

INNOVATE closes $360M 10.5% notes and $54M 9.5% convertible debt refinancing

Issued $360.3M New Senior Secured Notes (10.5%, due Feb 2027); exchanged $328.1M of existing 8.5% 2026 notes; $1.9M old notes remain.
August 5, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 7.01 item 9.01

INNOVATE Q2 revenue falls 23% to $242M; net loss of $22M vs prior-year profit of $14.1M

Revenue $242M, down 22.7% YoY; net loss of $22M vs net income $14.1M in Q2 2024.
July 31, 2025, 7:59 PM ET debt materiality 0.70 positive item 8.01 item 9.01

INNOVATE Corp. successfully exchanges 99.4% of 8.5% senior secured notes for 10.5% notes due 2027

US$328.1M of US$330M outstanding (99.41%) tendered for exchange; early settlement expected Aug 4, 2025.
July 17, 2025, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 8.01 item 9.01

INNOVATE launches $48.7M convertible exchange & $330M secured note exchange to extend debt maturities

Exchange of $48.7M 7.5% Convertible Notes due 2026 for $51.1M 9.5% Convertible Notes due 2027, secured by second-priority lien.
May 6, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

INNOVATE Q1 revenue $274.2M (-13% YoY); net loss widens to $24.8M; MediBeacon TGFR gets FDA approval

Revenue $274.2M, down 13% YoY; net loss attributable to common $24.8M ($1.89 per share), vs $17.7M loss YoY.
March 31, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

INNOVATE reports Q4 revenue down 34.5% to $236.6M; net loss widens to $16.9M; MediBeacon TGFR receives FDA approval

Q4 2024 revenue $236.6M (-34.5% YoY); net loss attributable to common $16.9M ($1.29 loss per share).
March 6, 2025, 6:59 PM ET debt materiality 0.60 neutral item 8.01 item 9.01

INNOVATE extends revolving credit facility maturity to Aug 1, 2025

Sixth Amendment to Credit Agreement dated March 13, 2020, with MSD PCOF Partners IX, LLC as lender.
February 25, 2025, 6:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

MediBeacon's Transdermal GFR Monitor and Sensor approved by China NMPA; Lumitrace under review

China NMPA approved MediBeacon TGFR Monitor and Sensor for kidney function assessment; Lumitrace injection still under review, target approval late 2025.
January 21, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

MediBeacon TGFR System Receives FDA Approval for Kidney Function Assessment

FDA approved MediBeacon Transdermal GFR (tGFR) for assessing kidney function in adults with normal or impaired renal function without input of age, sex, race.
November 20, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

INNOVATE portfolio co R2 Technologies reports record Q2/Q3: unit sales up 294% YoY

R2 Q2/Q3: 294% increase in worldwide Glacial Skin system unit sales vs prior year.
November 6, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 7.01 item 9.01

INNOVATE Q3 revenue $242.2M (-35.5% YoY); net loss $15.3M vs $7.3M loss YoY

DBM Global revenue $232.8M (-37% YoY); gross margins expanded 360 bps to 18.8%
August 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

INNOVATE Q2 net income $14.1M vs loss $10.5M YoY; revenue $313M (-15%), adj. EBITDA $26.7M

Revenue $313.1M (-15.1% YoY); net income $14.1M vs loss $10.5M; diluted EPS $0.10 vs ($0.13).
June 20, 2024, 7:59 PM ET other material materiality 0.75 negative item 3.02 item 5.03 item 5.07 item 9.01

INNOVATE shareholders approve reverse split, authorized shares increase; 44.7M shares converted

Shareholders approved reverse stock split of common stock (69.5M for, 3.6M against).
May 7, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

INNOVATE Q1 revenue $315M (-0.8%); net loss $17.7M, adj EBITDA $12.8M (+161%)

Revenue $315.2M (down 0.8% YoY); net loss attributable to common $17.7M vs $10.2M loss in Q1 2023.
April 24, 2024, 7:59 PM ET other material materiality 0.70 neutral item 3.02 item 8.01 item 9.01

INNOVATE Corp. closes rights offering, raising $35M from common shares and Lancer Capital preferred stock.

Rights offering expired Apr. 19, 2024; 5.3M common shares at $0.70/share raised $3.7M in gross proceeds.
April 22, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

INNOVATE Corp. announces preliminary results of rights offering; expects ~$35M gross proceeds

18.1M basic subscription rights exercised to purchase 5.2M shares of common stock at $0.70/share.
March 28, 2024, 7:59 PM ET other material materiality 0.65 positive item 3.02 item 5.03 item 9.01 ◈ Governance Changes

INNOVATE Corp. raises $25M via Series C convertible preferred sale to Lancer Capital

Issued 25,000 shares of Series C Non-Voting Convertible Preferred to Lancer Capital for $25M.

Earnings & guidance

2026-Q1 EPS reported -$1.29 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

19 positive 5 negative 15 neutral

source · VATE on sec.gov